{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:26:11Z","timestamp":1787729171269,"version":"build-2784847793"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Anaplastic thyroid cancer (ATC) is a rare and rapidly fatal human cancer. Its usual treatment includes the combination of surgery, external hyperfractionated radiation therapy, and chemotherapy. These treatments permit achieving about 6\u201310 months of median survival. For this reason, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit. Until now, the effect of pazopanib in primary human ATC cells (pATC) has not been reported in the literature. The aim of our study was to evaluate in vitro the antineoplastic effect of pazopanib in pATC. Surgical thyroidal tissues were collected from five patients with ATC, from thyroid biopsy at the moment of first surgical operation. An inhibition of proliferation, migration, and invasion, and an increase in apoptosis were demonstrated upon treating pATC cells with pazopanib (p &lt; 0.05). Moreover, pazopanib was able to significantly decrease the VEGF expression in pATC cells (p &lt; 0.05). To conclude, in this study, we demonstrate the antineoplastic activity of the antiangiogenic inhibitor, pazopanib, in human pATC in vitro.<\/jats:p>","DOI":"10.3390\/ijms24032398","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T01:57:07Z","timestamp":1674698227000},"page":"2398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture"],"prefix":"10.3390","volume":"24","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical and Molecular Pathology and of Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical and Molecular Pathology and of Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mazzi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical and Molecular Pathology and of Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-4794","authenticated-orcid":false,"given":"Armando","family":"Patrizio","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Piaggi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-1386","authenticated-orcid":false,"given":"Enke","family":"Baldini","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-1649","authenticated-orcid":false,"given":"Marco","family":"Centanni","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Latina, Italy"},{"name":"Endocrine Unit, AUSL Latina, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-5431","authenticated-orcid":false,"given":"Concettina","family":"La Motta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6342","authenticated-orcid":false,"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical and Molecular Pathology and of Critical Area, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","article-title":"Molecular targets of tyrosine kinase inhibitors in thyroid cancer","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Galdiero, M.R., Ruffilli, I., Elia, G., Ragusa, F., Paparo, S.R., Patrizio, A., Mazzi, V., and Varricchi, G. (2019). Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184413"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/med.21448","article-title":"Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells","volume":"37","author":"Antonelli","year":"2017","journal-title":"Med. Res. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"Baudin","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archsurg.133.1.89","article-title":"Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident","volume":"133","author":"Miccoli","year":"1998","journal-title":"Arch. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","article-title":"Novel treatments for anaplastic thyroid carcinoma","volume":"9","author":"Ferrari","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1089\/thy.2009.1599","article-title":"Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: The 2009 revision","volume":"19","author":"Wartofsky","year":"2009","journal-title":"Thyroid"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1574892813666180220110729","article-title":"Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied","volume":"13","author":"Ferrari","year":"2018","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867324666171006165942","article-title":"Sunitinib in the Treatment of Thyroid Cancer","volume":"26","author":"Ferrari","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/138920211798120808","article-title":"New targeted therapies for thyroid cancer","volume":"12","author":"Antonelli","year":"2011","journal-title":"Curr. Genom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer","volume":"21","author":"Nair","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_13","unstructured":"(2022, October 25). FDA Approves Cabozantinib for Patients With Previously Treated Radioactive Iodine\u2013Refractory Differentiated Thyroid Cancer. Available online: https:\/\/ascopost.com\/issues\/october-10-2021\/fda-approves-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/thy.2017.0285","article-title":"Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_20","first-page":"2306","article-title":"Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fendo.2018.00764","article-title":"Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration","volume":"9","author":"Ferrari","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1210\/jc.2013-2321","article-title":"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"99","author":"Antonelli","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1210\/jc.2011-1987","article-title":"CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"97","author":"Antonelli","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12020-015-0717-4","article-title":"CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation","volume":"53","author":"Fallahi","year":"2016","journal-title":"Endocrine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","article-title":"Flasks fibres and flanks\u2014Pre-clinical tumour models for predicting clinical antitumour activity","volume":"84","author":"Newell","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_26","first-page":"310","article-title":"Is there a role for chemosensitivity tests in head and neck cancer?","volume":"27","author":"Dollner","year":"2004","journal-title":"Onkologie"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/0277-5379(90)90165-P","article-title":"Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer","volume":"26","author":"Schroyens","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semcancer.2020.06.013","article-title":"Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1089\/thy.2019.0269","article-title":"An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer","volume":"30","author":"Bible","year":"2020","journal-title":"Thyroid"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.07.029","article-title":"PAZOTHYR investigators. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR","volume":"157","author":"Godbert","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"166ra3","DOI":"10.1126\/scitranslmed.3004358","article-title":"Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer","volume":"5","author":"Isham","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3389\/fonc.2019.01202","article-title":"Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells","volume":"9","author":"Orlandi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/thy.2015.0518","article-title":"Primary Cell Culture Systems for Human Thyroid Studies","volume":"26","author":"Wang","year":"2016","journal-title":"Thyroid"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/thy.2009.0195","article-title":"Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer","volume":"19","author":"Pilli","year":"2009","journal-title":"Thyroid"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2265.2008.03415.x","article-title":"Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells","volume":"70","author":"Antonelli","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EJE-08-0190","article-title":"Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration","volume":"159","author":"Antonelli","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_38","first-page":"148","article-title":"Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests","volume":"69","author":"Antonelli","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1677\/ERC-08-0337","article-title":"Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: Modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"16","author":"Antonelli","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:15:46Z","timestamp":1760120146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032398"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032398","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}